JointHealth™ express April 21, 2016
Reminder: Patient input on treatment for rheumatoid arthritis and ankylosing spondylitis needed
Do you have rheumatoid arthritis or ankylosing spondylitis or care for someone who does? We want your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for SEB etanercept for the treatment of rheumatoid arthritis or ankylosing spondylitis. The innovator biologic, or reference product, is etanercept (Enbrel®). Here are the questions they are asking.
Please send us your input by Monday, April 25, 2016, so that we may make a submission by the April 28 deadline. Please contact us at feedback@jointhealth.org to provide your input or arrange for a phone interview at 604-974-1366.
Reminder: Patient input on treatment for rheumatoid arthritis and ankylosing spondylitis needed
Do you have rheumatoid arthritis or ankylosing spondylitis or care for someone who does? We want your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for SEB etanercept for the treatment of rheumatoid arthritis or ankylosing spondylitis. The innovator biologic, or reference product, is etanercept (Enbrel®). Here are the questions they are asking.
Please send us your input by Monday, April 25, 2016, so that we may make a submission by the April 28 deadline. Please contact us at feedback@jointhealth.org to provide your input or arrange for a phone interview at 604-974-1366.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.